US4472508A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Test for detecting and measuring the graves' disease-specific immunoglobulins
Assignee: Beth Israel Deaconess Medical Center
•
Filing: 1982-12-30
•
Granted: 1984-09-18
•
Expires: 2002-12-30
Abstract
Abstract An immunoassay for a specific antibody, particularly Graves' disease-specific antibody, in which interfering reactions by the reactive ends of similar antibodies are eliminated by the step of occluding the interfering reactive ends with an antibody against the interfering reactive ends.
Inventors
- 👤 Sidney H. Ingbar
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 09:36
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/564; Y; Y10; Y10S; Y10S436/00; Y10S436/804; Y10S436/811; Y10S436/825
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
66 words
An immunoassay for Graves'-specific antibodies comprising the steps of: (a) preparing an IgG fraction from test serum; (b) creating a solid-phase system by interacting the test IgG fraction with an antibody against the F c fragment of human IgG; (c) radioactively labeling membranes containing thyroid-stimulating hormone receptors; (d) adding the labeled membranes to the solid-phase system; (e) incubating the mixture; and (f) counting precipitated labeled membrane.
Claim 2
Dependent Claim
66 words
An immunoassay for Graves'-specific antibodies comprising the steps of: (a) preparing an IgG fraction from test serum; (b) creating a solid-phase system by interacting the test IgG fraction with an antibody against the F c fragment of human IgG; (c) radioactively labeling membranes containing thyroid-stimulating hormone receptors; (d) adding the labeled membranes to the solid-phase system; (e) incubating the mixture; and (f) counting precipitated labeled membrane.
Claim 3
Dependent Claim
64 words
An immunoassay for Graves'-specific antibodies comprising the steps of: (a) coupling an antibody against the F c fragment of human IgG to a solid phase matrix; (b) incubating whole test serum with the coupled, solid phase antibody; (c) radioactively labeling membranes containing thyroid-stimulating hormone receptors; (d) adding the labeled membranes to the solid-phase system; (e) incubating the mixture; and (f) counting precipitated label membrane.
Claim 4
Dependent Claim
64 words
An immunoassay for Graves'-specific antibodies comprising the steps of: (a) coupling an antibody against the F c fragment of human IgG to a solid phase matrix; (b) incubating whole test serum with the coupled, solid phase antibody; (c) radioactively labeling membranes containing thyroid-stimulating hormone receptors; (d) adding the labeled membranes to the solid-phase system; (e) incubating the mixture; and (f) counting precipitated label membrane.
Claim 5
Dependent Claim
14 words
The immunoassay of claims 1 or 2 wherein the membranes comprises human thyroid membranes.
Claim 6
Dependent Claim
16 words
The immunoassay of claims 1 or 2 wherein the membranes comprise guinea pig fat cell membranes.
Claim 7
Dependent Claim
15 words
The immunoassay of claims 1 or 2 wherein the membranes are labeled with 125 I.
Claim 8
Dependent Claim
14 words
The immunoassay of claim 2 wherein in step a, a coupling agent is included.
Claim 9
Dependent Claim
12 words
The immunoassay of claim 6 wherein the coupling agent is cyanogen bromide.
Claim 10
Dependent Claim
28 words
In an immunoassay for a specific antibody in which similar antibodies have interfering reactive ends, the improvement which comprises occluding the interfering reactive ends of the similar antibodies.
Claim 11
Dependent Claim
28 words
In an immunoassay for a specific antibody in which similar antibodies have interfering reactive ends, the improvement which comprises occluding the interfering reactive ends of the similar antibodies.
Claim 12
Dependent Claim
24 words
The improvement of claim 8 wherein the interfering reactive ends are occluded by interacting the antibodies with an antibody against the interfering reactive end.
Claim 13
Dependent Claim
17 words
The assay of claim 9 wherein the reactive end is the F c region of the antibody.
Claim 14
Dependent Claim
50 words
In an immunoassay for a specific antibody in a mixture of antibodies, in which the antibody is measured by binding of said antibody to a labelled antigen, the improvement which comprises first occluding the non-antigen binding portions of the antibodies and then binding said specific antibody to said labelled antigen.
Claim 15
Dependent Claim
50 words
In an immunoassay for a specific antibody in a mixture of antibodies, in which the antibody is measured by binding of said antibody to a labelled antigen, the improvement which comprises first occluding the non-antigen binding portions of the antibodies and then binding said specific antibody to said labelled antigen.
Claim 16
Dependent Claim
20 words
The improvement of claim 11 wherein said non-antigen binding portion of the antibody is the Fc region of the antibody.
Claim 17
Dependent Claim
22 words
The improvement of claim 11 wherein said specific antibody binds to said labelled antigen at the F ab region of the antibody.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-09-18 | 1988-03-19 | 1988-09-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-09-18 | 1992-03-19 | 1992-09-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-09-18 | 1996-03-19 | 1996-09-18 | $7700.00 | Window Closed / Lapsed |